Adenosine A1-A3 AMPA α-amino-3-hydroxyl-5-methyl-4isoxazole-propionate AR Androgen AT Angiotensin II BzR Peripheral-type benzodiazepene CA I-V Carbonic anhydrase I-V D [1] [2] [3] [4] Dopamine D 1 A second retrospective test predicted targets for the 3,665 drugs uncharacterized in either database but known in the literature. Of the 6,928 drug off-targets predicted, we discarded 430 as highly similar by structure to known target ligands, and another 2,666 as trivial. This left 3,832 predictions, of which we inspected 184 by literature search and by interrogating other databases. Of these, 42 turned out to be known associations ( Supplementary Table 3 ). For instance, when we screened the drug Revanil (lisuride) against the MDDR ligand-target sets, its best E-value was as an a 2 adrenergic antagonist, and when we screened the drug Permax (pergolide) it had an E-value of 8.70 3 10 229 as a 5-HT 1D receptor agonist. Consistent with these predictions, Revanil has been reported to bind adrenergic a 2 at 0.055 nM and Permax binds the 5-HT 1D receptor at 13 nM ( Supplementary Table 3 ), although neither activity was reported in the MDDR or WOMBAT databases.
New drug-target predictions
For many of these 184 predictions we found no literature precedent. We therefore tested 30 predictions that were experimentally accessible to us. In radioligand competition binding assays, 23 of these (77%) yielded inhibition constants (K i values) less than 15 mM (lower K i values indicate higher affinity) (Tables 1 and 2 and Supplementary  Fig. 1 ). Fifteen of these 23 were to aminergic G-protein-coupled receptors (GPCRs) ( Table 1) , and the remainder crossed major receptor classification boundaries (Table 2 ). For instance, the a 1 antagonist Doralese was predicted and observed to bind to the dopamine D 4 receptor-both a 1 and D 4 are aminergic GPCRs. Conversely, the HIV-1 reverse transcriptase (enzyme) inhibitor Rescriptor was predicted and observed to bind to histamine H 4 receptor (GPCR); this prediction crosses major target boundaries. For several predictions, we tested multiple receptor subtypes because the MDDR left these unspecified; for example, for a predicted 'a 1 adrenergic blocker', we tested the drug at a 1A , a 1B and a 1D subtypes; we count these as a single target. In total, 14 drugs bound 23 previously unknown targets, with 13 having sub-micromolar and five having sub-100 nM affinities (Tables 1 and 2 ). In cases such as Doralese's, the affinity for the discovered off-target dopamine D 4 , to which it binds with a K i of 18 nM ( Fig. 2a ), was better than that for its known therapeutic targets, a 1A and a 1B adrenergic receptors, for which its K i values are 611 and 226 nM, respectively 27 .
The question arises as to how interesting and biologically relevant these new off-targets are. This can be evaluated by the following criteria: when the new targets contribute to the primary activity of the drug, when they may mediate drug side effects, or when they are unrelated by sequence, structure and function to the canonical targets. Although not all of the newly predicted off-targets fall into these three categories, several fall into each.
New targets as primary sites of action
The new targets can improve our understanding of drug action. DMT is an endogenous metabolite and a notorious hallucinogen. Recently, the molecule was characterized as a s 1 -receptor regulator at micromolar concentrations, an association implicated in its hallucinogenic properties 28, 29 . This surprised us because many drugs, including nonhallucinogens, bind promiscuously to the s 1 receptor with higher affinity than DMT 30 . Also, the hallucinogenic characteristics of DMT are consistent with other hallucinogens thought to act through serotonergic receptors, some of which the molecule is known to bind [31] [32] [33] . We therefore screened DMT against the 1,133 WOMBAT targets. SEA predicted it to be similar against multiple serotonergic (5-HT) ligand sets, with E-values ranging from 9.2 3 10 281 to 7.4 3 10 26 . Upon testing, we find DMT binds 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 5A , 5-HT 6 and 5-HT 7 receptors with affinities ranging from 39 nM to 2.1 mM (Supplementary Table 4 and Supplementary Fig. 2 ). Of these, three were previously unknown ( Table 1) , and all had substantially greater affinities for DMT than that represented by its 14.75 mM dissociation constant (K d ) for s 1 (ref. 28) . To investigate further the role of serotonin receptors in DMT-induced hallucination, we turned to a cell-based assay and an animal model that are predictive of hallucinatory actions 34 . Consistent with SEA prediction, we find that DMT is not only a potent partial agonist at 5-HT 2A (Fig. 2g ) as has been reported 31 , but it also induces head twitch response in wild-type but not in 5-HT 2A knockout mice ( Fig. 2h ), which is new to this study. The half-maximum effective concentration (EC 50 ) of DMT at 5-HT 2A is 100-fold lower (better) than that observed for s 1 (ref. 28 ). These observations support 5-HT 2A as the primary target for DMT's hallucinogenic effects.
Similarly, the new off-targets for Sedalande-a neuroleptic and anxiolytic derived from haloperidol-may illuminate this drug's therapeutic effects. Although used in psychiatric clinical trials as far back as the early 1960s 35 , neither its mechanism of action in the central nervous system (CNS), nor that of the related Dimetholizine, is well understood. In addition to new activities against a 1 adrenergic receptors (1.2-240 nM; Fig. 2b and Table 1 ), Dimetholizine was found to bind the D 2 and 5-HT 1A receptors, and Sedalande to bind the 5-HT 1D receptor ( Table 1 and Supplementary Fig. 1 ). This probably contributes to the CNS activity of both drugs, given the association of the former with anxiety and aggression modulation, and the activity of many antipsychotics against the D 2 receptor. We also found analogues of Sedalande that were active against 5-HT 1D , often at affinities comparable to or greater than those of Sedalande itself (Supplementary Table 5 and Supplementary Fig. 3 ). This supports the possibility of optimizing these drugs for new indications.
An example of a drug now being investigated for a new indication is Fabahistin. Used since the 1950s as a symptomatic antihistamine, Fabahistin is now being investigated for Alzheimer's disease. When screened against 1,133 WOMBAT targets, SEA found an extraordinary similarity to 5-HT 5A ligands, with an E-value of 2.0 3 10 258 . When we measured its binding to the 5-HT 5A receptor, Fabahistin had a K i of 130 nM ( Fig. 2c and Table 1 ). This is another example of a drug whose new, off-target affinity is much better than that for its canonical H 1 receptor target 36 . Its activity against 5-HT 5A and related serotonergic receptors 37 may have implications for Fabahistin's role as an Alzheimer's disease therapeutic.
Off-targets as side-effect mediators
Some of the new off-targets may contribute to a drug's adverse reactions. Motilium is an antiemetic and dopamine D 1/2 antagonist that achieves peak plasma concentrations of 2.8 mM 38 after intravenous administration. This formulation was withdrawn owing to adverse cardiovascular effects, with the FDA citing cardiac arrest, arrhythmias and sudden death 39 . Although Motilium binds the hERG channel with a half-maximum inhibitory concentration (IC 50 ) of 5 mM 40 , the 71-710 nM affinities observed here against a 1A , a 1B and a 1D may also contribute to these cardiovascular effects ( Fig. 2d , Table 1 and Supplementary Fig. 1) .
Similarly, the micromolar activity against the b adrenergic receptors of the widely used selective serotonin reuptake inhibitor (SSRI) antidepressants Prozac and Paxil ( Fig. 2e , Table 1 and Supplementary  Fig. 1 ) may explain several of their adverse effects. The abrupt withdrawal of Paxil raises standing heart rate, a symptom of the SSRI discontinuation syndrome 41 . This is counterintuitive, as relieving blockade of serotonin reuptake should reduce synaptic serotonin, inconsistent with the cardiovascular syndrome 42 . b-blockade by these SSRIs may partially explain this effect because b-blockers induce a similar rebound tachycardia after abrupt withdrawal, owing to b receptor upregulation and sensitization. Despite its higher affinity for b receptors, Prozac has a longer half-life than Paxil, and its withdrawal does not induce SSRI discontinuation syndrome. Also, SSRIs and many b-blockers can induce sexual dysfunction 43 . Because both serotonergic and adrenergic signalling are involved in sexual response, the binding of Paxil and Prozac to the b 1 -receptor may explain why they induce greater dysfunction than other SSRIs.
Drug binding across major protein boundaries
Whereas many of the predicted off-targets occur among aminergic GPCRs, a target class for which cross-activity is well-known (see later) 44 , four of the drugs bound to targets unrelated by sequence or structure to their canonical targets ( Table 2 ). For instance, the reverse transcriptase (enzyme) inhibitor Rescriptor was predicted and shown to bind to the histamine H 4 receptor, a GPCR. These two targets share no evolutionary history, functional role, or structural similarity whatsoever. Intriguingly, although the K i value of Rescriptor for the H 4 receptor is high at 5.3 mM ( Table 2 and Supplementary Fig. 1 ), this is within its steady-state plasma concentration (minimum plasma concentration averages 15 mM) and is consistent with the painful rashes associated with Rescriptor use 45 ; likewise, H 4 dysregulation has been associated with atopic dermatitis 46 . Similarly, the vesicular monoamine transporter (VMAT) inhibitor 47 Xenazine binds two different GPCRs at sub-micromolar concentrations ( Table 2 and Supplementary Fig. 1 ). Despite its use over the last 50 years, Xenazine has not been reported to bind to any GPCR. Finally, the selective ion-channel inhibitors Vadilex and RO-25-6981 were predicted and found to bind to GPCRs and to transporters to which they were previously unknown to bind (Fig. 2f , Table 2 and Supplementary Fig. 1 ). Although these ion-channel drugs have known polypharmacology (Fig. 3) , a key point is that the new targets for these four drugs are unrelated to their main therapeutic targets except in the similarity of the ligands that modulate their activities. More broadly, the protein target with the highest sequence similarity to any of a drug's known targets is rarely predicted by the SEA approach. Rather, the target predicted by ligand similarity is typically well down in the sequence-similarity ranking. Thus for Xenazine, the off-target a 2 adrenergic receptor is the 78th most similar receptor to the known target VMAT2 and in fact has no significant similarity at all, with a PSI-BLAST E-value of 125 (Supplementary Table 6 ); and for Rescriptor, H 4 is the 167th most similar receptor to HIV-1 reverse transcriptase, and even for Prantal, the aminergic d-opioid receptor is only the 26th most similar receptor to its known muscarinic M 3 target.
Certain caveats merit mention. Not all of the new off-targets predicted here would surprise specialists. For instance, Dimetholizine has antihypertensive activity and so its affinity for adrenergic receptors is not wholly unanticipated. Similarly, Kalgut is classified as a selective b 1 agonist, thought to have little activity on other adrenergic receptors 48 . Whereas the observation that it does bind to the b 3 receptor goes against this classification, structurally this seems easy to credit ( Table 1 and Supplementary Fig. 1 ). Indeed, 10 of the 14 drugs reported here are active against aminergic GPCRs (Fig. 3) , and so their cross-activities against other aminergic GPCRs have some precedent 44 . Finally, although most of the drugs were active at their predicted off-targets, one-third were not; these are examples of the false-positives to which this method is susceptible (Supplementary Table 7 ). Thus, the anxiolytics Valium and Centrax scored well against cholecystokinin B ligands, the antipsychotic Emilace was predicted to bind 5-HT 4 , the anaesthetic Duocaine the k-opioid receptor, the antihypertensive Doralese neurokinin receptors, and the narcotic Dromoran and the bradycardic Zatebradine scored well against the D 2 and D 1 receptors. None of these bound their predicted off-targets with affinities better than 10 mM. SEA ignores pharmacophores in its predictions, comparing drugs to ligand sets based on all shared chemical patterns. This is at once a strength, in that it is model-free, and a weakness, in that it may predict activity for drugs that share many features with the ligands of a target, and yet miss a critical chemotype.
Predicting polypharmacology on a large scale
Notwithstanding these caveats, it is the model-free nature of these predictions that allows a comprehensive exploration of drug-target interactions, most of which remain unexplored. We have focused on a thin slice of pharmacological targets, one dominated by aminergic drugs (Fig. 3) . Stepping back to view the larger picture, 364 additional off-targets for 158 drugs are predicted with E-values better than 1 3 10 250 , whereas 1,853 new off-targets are predicted with E-values better than 1 3 10 210 (Fig. 1b) . This compares to the only 972 off-target activities already annotated in the databases (Fig. 1a) . The SEA and related chemoinformatics methods [16] [17] [18] [19] [20] provide tools to explore these associations systematically, both to understand drug effects and explore new opportunities for therapeutic intervention.
METHODS SUMMARY
Prediction of off-targets. A collection of 3,665 FDA-approved and investigational drug structures was computationally screened against a panel of more than 1,400 protein targets. The drug collection was extracted from the MDL Comprehensive Medicinal Chemistry database. Each target was represented solely by its set of known ligands, which were extracted from three sources of annotated molecules: the MDL Drug Data Report, the WOMBAT 26 , and the StARlite databases. The two-dimensional structural similarity of each drug to each target's ligand set was quantified as an E-value using the SEA 21 . Experimental testing. Predicted off-targets with strong SEA E-values were evaluated for novelty against orthogonal databases and the literature. Those off-targets without precedent were subjected to radioligand competition binding assays using standard techniques 49 at the NIMH Psychoactive Drug Screening Program. The role of 5-HT 2A agonism in DMT-induced hallucination was examined in cell-based and in knockout mouse models 34 . Derivatives of Sedalande were identified in the ZINC 50 database by substructure search, and their affinities for 5-HT 1D tested using standard techniques 49 . Drug-target networks and out-group analysis. Comprehensive networks of known drug-target associations (by WOMBAT) and predicted off-targets (by SEA) were constructed. Furthermore, SEA off-target predictions were compared to those derived from naive Bayesian classifiers and from PSI-BLAST 21-23 comparisons of a drug's known protein target(s) against the panel of potential protein targets. 
METHODS
Ligand sets. We extracted ligand sets from databases that annotate molecules by therapeutic or biological category. For example, the 2006.1 MDDR contains 518 molecules annotated as a 1 adrenergic receptor blockers, which we grouped into a single 'a 1 adrenergic blocker' set. As ligand reference sources, we used the three databases shown in Supplementary Table 8 . The first was a subset of the 2006.1 MDDR, prepared as previously described 21, 23 . The second was the 2006.2 WOMBAT database 26 , processed as earlier. We collapsed WOMBAT targets across species and organized them into inhibitory, activating and unspecified-binding classes. All ligands with affinities worse than 1 mM to their targets were removed. This left 1,133 classes built from 191,943 ligands with median and mean of 37 and 169 ligands per target class. The third database was StARlite, which we also processed as above. We extracted StARlite annotations at the two highest confidence levels (5 and 7), discarded those with affinities worse than 1 mM, and organized them into target classes. This The 1,216 drugs used to link protein targets in the drug-target networks (Fig. 1) were downloaded from the 2008 EPA Distributed Structure-Searchable Toxicity (DSSTox) Database at http://www.epa.gov/NCCT/dsstox/, and prepared as earlier.
Ligand activity predictions. We compared each drug individually against each set of ligands. Molecules were represented by two topological descriptors: 2048-bit Daylight 51 and 1024-bit folded ECFP_4 fingerprints 23 . We used the SEA 21,23 using each descriptor separately and chose top-scoring hits (that is, those with small E-values) from each such 'screen' independently.
The initial SEA screens of 3,665 CMC drugs against 246 MDDR targets yielded 901,590 drug-target comparisons, and we subjected these to retrospective literature analysis and prospective empirical testing. However, we later extended SEA screens to WOMBAT and StARlite databases, comprising 4,152,445 and 4,244,070 drug-target comparisons, respectively. We have not mined these expanded SEA screens for retrospective validations; instead we used them only to conduct prospective tests. Supplementary Table 8 records the screen (that is, database) from which each prediction in Tables 1 and 2 is derived. To compare SEA predictions against those of naive Bayesian classifiers ( Supplementary Table 1 ), we implemented a Laplacian-corrected naive Bayesian classifier with Avidon weighting, as previously described 23 . Drug-target and target-target networks. The drug-target networks in Fig. 1 are bipartite; along any given path, nodes alternate between protein targets and the drugs that link them. Targets are from WOMBAT and drugs are from EPA DSSTox. Red edges denote SEA predictions with E-values # 10 210 . Predictions already reported in WOMBAT at K i # 1 mM are shown as additional grey edges. All networks were generated in Cytoscape 2.6.1 (ref. 52). Figure 3 is a bipartite graph linking drugs from Tables 1 and 2 with protein targets. Grey edges link drugs to known targets from manual literature and database search. Grey edges denote binding at #1 mM, except when no K i value was available; in these three cases (Xenazine-VMAT2, Prantal-M 3 and Fabahistin-H 1 ), the link was included for completeness. WOMBAT out-group analysis. We mapped 204 MDDR activity classes to matching WOMBAT targets in two phases. In the first, we mapped 87 MDDR activity classes using EC numbers from the Schuffenhauer ontology 25 to those present in WOMBAT. We second mapped a further 118 non-enzyme MDDR activity classes by supervised sub-phrase matching ( Supplementary Tables 9 and  10 ). Although this mapping is not guaranteed to be exhaustive, it is correct to the best of our knowledge.
We then extracted all molecules marked 'drug' in WOMBAT (746 unique). Using SEA, we compared them against the mapped MDDR classes only, and discarded all trivial hits (that is, those in which the drug was already annotated in that MDDR class as a ligand). We asked how many of these were, in retrospect, substantiated by the existing WOMBAT annotations, at affinities #1 mM. Sequence similarity comparison. We associated each drug in Fig. 3 with the human FASTA sequences of its known and its new protein targets, using http:// www.uniprot.org. We ran these sequences by PSI-BLAST (BLAST version 2.2.14, default parameters) 21-23 against a subset of MDDR targets that we prepared as previously described 21 . For each SEA prediction in Fig. 3 , we reported the best direct PSI-BLAST match (along with its E-value and ranking) of the new protein target to any of that drug's previously known protein targets (Supplementary Table 6 ). Our goal was to address whether starting with the best choice from a drug's known protein targets, we could recapitulate each SEA prediction solely by sequence similarity. Experimental testing. Radioligand binding and functional assays were performed as previously described 49, 53 . Detailed experimental protocols are available on the NIMH PDSP website at http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf. Mice. All experiments were approved by the Institutional Animal Care and Use Committee at the University of North Carolina, Chapel Hill. Mice were housed under standard conditions: 12 h light/dark cycle and food and water ad libitum. Head twitch. Littermate pairs of 5-HT 2A wild-type and knockout mice were pretreated for 2 h with 75 mg kg 21 pargyline, intraperitoneally, prepared in sterile saline (0.9% NaCl) (Sigma-Aldrich). Mice were then injected with sterile saline or 1.0 mg kg 21 DMT, intraperitoneally, prepared in sterile saline and moved to a new cage. Head twitch behaviour, which consists of a rapid, rotational flick of the head about the axis of the neck, was counted over 15 min. We have determined that trained observers count the same number of head twitches whether blinded or unblinded to genotype (data not shown). We confirmed that this was the case with three littermate pairs, and the rest of the studies were performed by one unblinded observer 34 . 
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